How Painkillers Reduce Pain Signals

Ibuprofen and morphine are both called painkillers, but they interrupt pain through entirely different biological systems. One blocks the chemical trigger for pain at the site of injury; the other blocks the nervous system's ability to transmit and register a pain signal it has already received. This distinction, mechanism of action rather than "strength," is what actually determines which drug helps which kind of pain, and it is also what determines which drug classes carry which risks. This article explains those mechanisms as pharmacology, not as guidance on what to take. It does not recommend any medication, dose, or use case, and it treats the very real risks of dependence and overdose associated with opioids with the seriousness they warrant.

What "pain" actually is, biologically

Before any drug mechanism makes sense, it helps to understand what a pain signal is in the first place. Pain begins with nociceptors, specialized sensory nerve endings distributed through skin, muscle, joints, and internal organs that detect potentially damaging stimuli, extreme heat, mechanical pressure, or chemical irritation, and convert that stimulus into an electrical signal. This conversion process is called transduction, and it is the first of four stages that pain physiologists generally describe: transduction (the injury site generates a signal), transmission (the signal travels along nerve fibers to the spinal cord and brain), modulation (the signal is amplified or dampened at various checkpoints along the way), and perception (the brain constructs the conscious experience of pain from that processed signal).

Every painkiller class intervenes at a different one of these stages, which is the single most useful fact for understanding why no single drug works well for every kind of pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) intervene at transduction, right at the injury site, before the signal is even generated at full strength. Opioids intervene at transmission and modulation, inside the spinal cord and brain, after the signal is already traveling. Acetaminophen appears to act somewhere in between, primarily within the central nervous system, though its precise site and mechanism remain incompletely characterized even after more than a century of clinical use.

This four-stage framework also explains a fact that surprises many people: pain is not a passive readout of tissue damage. The same nociceptor signal can be amplified by inflammation or dampened by the body's own endogenous opioid system, meaning the intensity of pain a person consciously experiences is not a fixed, one-to-one translation of how much tissue damage actually occurred. Chronic stress, prior pain experience, and even attention can shift how strongly a given signal registers, which is part of why pain science increasingly treats pain as a constructed perception rather than a simple alarm bell.

How NSAIDs block the pain trigger at its source

NSAIDs, a class that includes ibuprofen, aspirin, and naproxen, work by inhibiting a pair of enzymes called cyclooxygenase-1 and cyclooxygenase-2, abbreviated COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid, a fatty acid released from damaged cell membranes, into prostaglandins, a family of lipid signaling compounds. Prostaglandins do not directly cause pain on their own; instead, they sensitize nearby nociceptors, lowering the threshold at which those nerve endings fire and making surrounding tissue more reactive to stimuli that would not normally register as painful, a phenomenon called peripheral sensitization.

By inhibiting COX-1 and COX-2, NSAIDs reduce prostaglandin synthesis at the site of tissue damage, which reduces both the inflammatory swelling associated with injury and the heightened pain sensitivity that inflamed tissue produces. This is a mechanistic intervention at the transduction stage of pain: NSAIDs reduce how strong a signal gets generated in the first place, rather than altering how the brain processes a signal once it arrives. It is the reason NSAIDs are particularly effective for pain with a clear inflammatory component, sprains, arthritis flare-ups, muscle strain, menstrual cramps, since those conditions specifically involve elevated local prostaglandin activity.

The same mechanism that produces the benefit also produces the most common downside. COX-1, in particular, is not only involved in inflammatory pain signaling; it also plays a protective, "housekeeping" role throughout the body, including in the stomach, where COX-1-derived prostaglandins help maintain the mucus layer that protects the stomach lining from its own acid. Suppressing COX-1 activity therefore reduces that protective mucus production, which is a well-documented reason long-term NSAID use is associated with a higher risk of gastrointestinal irritation and ulcers. Selective COX-2 inhibitors were developed specifically to try to spare COX-1's protective stomach function while still blocking the COX-2 activity responsible for inflammatory pain, though COX-2 selectivity introduced its own separate cardiovascular risk profile, which is why the FDA requires cardiovascular warning labeling on NSAID products generally.

Why do NSAIDs work well for inflammation but not for nerve pain?

NSAIDs specifically target the prostaglandin-driven sensitization pathway that accompanies tissue damage and inflammation. Nerve pain, by contrast, often originates from damaged or abnormally firing nerve cells themselves rather than from ongoing prostaglandin release, so reducing prostaglandin synthesis does little to address a signal that is not being generated through that pathway in the first place.

COX-1 and COX-2 are structurally similar enzymes, but COX-1 is expressed continuously throughout the body for protective housekeeping functions (including stomach lining maintenance), while COX-2 is induced primarily at sites of injury or inflammation. This structural overlap is why non-selective NSAIDs, which block both, relieve pain effectively but also carry gastrointestinal risk that more COX-2-selective drugs were designed to reduce.

How opioids intervene in the nervous system itself

Opioids, a class that includes morphine, oxycodone, codeine, and fentanyl, work through a mechanism entirely distinct from NSAIDs. Rather than reducing signal generation at an injury site, opioids act on opioid receptors, primarily the mu-opioid receptor, found throughout the peripheral sensory neurons, spinal cord, brainstem, and brain. Mu-opioid receptors are G protein-coupled receptors, a large class of cell-surface receptors that trigger internal cellular changes when activated by a binding molecule, and when an opioid binds to one, the receptor signals through an inhibitory G protein pathway that reduces neuronal excitability, largely by increasing potassium ion flow out of the neuron and inhibiting voltage-gated calcium channels, both of which make the neuron less likely to fire and transmit a signal onward, according to a mechanistic review published in the NIH's NCBI Bookshelf (StatPearls, updated periodically).

This receptor system is not something opioid drugs invented access to; it already exists in the body as the endogenous opioid system, activated naturally by compounds the body produces itself, including beta-endorphin, a peptide derived from a larger precursor molecule called proopiomelanocortin and released by the hypothalamus during stress and vigorous exercise. Opioid painkillers work by mimicking these endogenous signaling molecules at the same mu-opioid receptors, according to research summarized in Frontiers in Systems Neuroscience (2022). This is the biological basis of the so-called "runner's high": intense exercise triggers release of the body's own endorphins, which activate the same receptor family that morphine and oxycodone activate directly.

Because mu-opioid receptors are distributed at multiple points along the pain pathway, spinal cord, brainstem, and higher brain regions involved in emotional processing, opioids do not just reduce how strongly a pain signal is transmitted upward; they also blunt the brain's affective, emotional response to whatever signal does arrive, reducing the perceived unpleasantness of pain even when the underlying signal has not fully diminished. This dual action, on both transmission and the emotional experience of pain, is part of why opioids can provide relief for severe pain sources that NSAIDs cannot meaningfully touch, including many types of post-surgical, traumatic, and cancer-related pain.

Why do opioids work for pain types that NSAIDs cannot address?

Opioids act centrally, on the nervous system's own transmission and perception machinery, rather than at the local site of tissue injury. This means they can reduce the felt intensity of a pain signal regardless of what generated it, which is why they remain clinically useful for severe pain where the injury itself cannot be meaningfully reduced by anti-inflammatory action alone.

Why the same receptor system creates dependence risk

The mu-opioid receptor's location is not limited to pain pathways. It is also densely expressed in the brain's mesolimbic reward circuitry, the same dopamine-linked system involved in motivation and reinforcement learning. When opioid drugs activate mu-opioid receptors in this circuitry, they can produce euphoria in addition to analgesia, and repeated activation of this reward pathway is a documented driver of the compulsive drug-seeking behavior that characterizes opioid use disorder.

Separately from reward-driven dependence, the nervous system adapts physiologically to sustained opioid receptor activation through a well-documented process called neuroadaptation. With repeated exposure, mu-opioid receptors undergo desensitization, meaning cellular mechanisms including receptor phosphorylation, beta-arrestin protein binding, and receptor internalization progressively reduce how strongly a given amount of drug activates the receptor, according to a molecular mechanisms review in Experimental and Therapeutic Medicine (Spandidos Publications, 2021). This receptor-level adaptation is the physiological basis of tolerance, the need for escalating amounts of a drug to achieve the same analgesic effect over time, and it is a distinct, separate phenomenon from psychological addiction, though the two frequently co-occur and reinforce each other in clinical practice.

This receptor-level adaptation also underlies physical dependence: because the nervous system has adjusted its own baseline signaling to compensate for the drug's chronic presence, removing the drug abruptly leaves the system under-compensated, producing withdrawal symptoms that reflect the nervous system's temporarily unbalanced state rather than a simple return to a pre-drug baseline. None of this is a minor pharmacological footnote. The United States Centers for Disease Control and Prevention's provisional data recorded approximately 82,998 predicted opioid-involved overdose deaths in the 12 months ending December 2022 (CDC National Center for Health Statistics, 2023), a figure the CDC and National Institute on Drug Abuse both attribute substantially to the increasing presence of illicitly manufactured synthetic opioids, including fentanyl, in the drug supply. This is a documented public health crisis, not a background detail, and it is a direct consequence of the same receptor biology that makes opioids effective analgesics: the mechanism that relieves pain and the mechanism that creates dependence risk are not separable side pathways, they are overlapping functions of the same receptor system.

Acetaminophen's mechanism: real, but still not fully mapped

Acetaminophen (known as paracetamol outside the United States) is one of the most widely used analgesics in the world, and yet its precise mechanism of action remains only partially understood, a genuinely unusual state of affairs for a drug in use since the mid-20th century. Unlike NSAIDs, whose COX-inhibition mechanism is well characterized biochemically, acetaminophen appears to act predominantly within the central nervous system rather than at peripheral injury sites, and current pharmacological research points toward a mechanism involving a metabolite of acetaminophen interacting with pathways related to prostaglandin synthesis specifically within the brain and spinal cord, potentially alongside effects on the body's own endocannabinoid and descending pain-inhibition systems.

This incomplete mechanistic picture is not a marginal academic detail; it explains a clinically important pattern. Acetaminophen reliably reduces pain and fever, yet it produces minimal anti-inflammatory effect at typical use compared to NSAIDs, which is inconsistent with a simple peripheral COX-inhibition model like the one that explains NSAIDs. If acetaminophen worked the same way NSAIDs do, just less potently, it should reduce peripheral inflammation to a similar (if smaller) degree. It largely does not, which is part of the evidence pointing toward a distinct, centrally weighted mechanism rather than a weaker version of the NSAID pathway.

Acetaminophen's primary safety concern is also mechanistically distinct from either NSAIDs or opioids. It is metabolized primarily by the liver, and a small fraction of a given dose is converted through a cytochrome P450 pathway into a reactive, toxic intermediate called NAPQI, which the liver normally neutralizes using its own glutathione stores. At quantities exceeding what the liver's glutathione reserves can safely neutralize, this pathway is responsible for acetaminophen's well-documented risk of severe liver injury, a mechanism entirely unrelated to prostaglandin synthesis or opioid receptor activity. Because this metabolic pathway runs through the liver, it connects to broader questions about how the liver detoxifies blood, the same organ system responsible for processing nearly every drug that enters the bloodstream.

A side-by-side view of mechanism, not strength

The table below compares the three major analgesic classes strictly by biological mechanism, where in the pain pathway each one intervenes, rather than by relative potency or appropriate use, which is a clinical decision outside the scope of a mechanism explainer.

Drug class	Primary target	Site of action	Pain-pathway stage affected	Key mechanistic risk
NSAIDs (ibuprofen, naproxen, aspirin)	COX-1 / COX-2 enzymes	Peripheral injury site	Transduction (signal generation)	Reduced protective stomach-lining prostaglandins; cardiovascular risk with COX-2-selective agents
Acetaminophen (paracetamol)	Not fully characterized; likely central prostaglandin-related pathway	Central nervous system	Modulation / perception (not well mapped)	Liver metabolite (NAPQI) accumulation exceeds glutathione capacity
Opioids (morphine, oxycodone, codeine, fentanyl)	Mu-opioid receptor (G protein-coupled)	Spinal cord, brainstem, brain	Transmission and perception	Receptor desensitization drives tolerance; reward-circuit overlap drives dependence risk

Three analgesic classes act at three different stages of the pain pathway, which is why "strength" is a misleading way to compare them, and why combining lower doses across mechanisms, rather than escalating one drug alone, is a recognized clinical strategy called multimodal analgesia.

Why chronic and neuropathic pain often resist all three mechanisms

Chronic pain, and neuropathic pain specifically, arising from damaged, compressed, or abnormally firing nerve tissue rather than from ongoing tissue injury or active inflammation, frequently responds poorly to NSAIDs, acetaminophen, and even standard opioid dosing. The reason traces directly back to the mechanisms described above: NSAIDs address prostaglandin-driven peripheral sensitization, which is largely absent in neuropathic pain; opioids reduce transmission and blunt perception of a signal, but a nerve that is generating spontaneous, abnormal electrical activity on its own keeps producing a signal that opioids can dampen only partially.

This is why neuropathic pain conditions, diabetic neuropathy, post-shingles nerve pain, and certain forms of chronic back pain involving nerve compression, are often managed instead with drug classes developed originally for entirely different purposes: anticonvulsants such as gabapentin, which stabilize abnormal electrical firing in nerve cells by acting on voltage-gated calcium channels, and certain antidepressants that modulate the descending pain-inhibition pathways running from the brainstem down the spinal cord. Neither of these drug classes works through COX inhibition or mu-opioid receptor binding at all; they intervene at a different point in the nervous system's own signal-generation and modulation circuitry.

This distinction is why accurate pain classification, distinguishing inflammatory (nociceptive) pain, nerve-damage (neuropathic) pain, and centrally amplified pain seen in some chronic pain syndromes, is a meaningful diagnostic step rather than a formality. Prescribing a drug mismatched to a pain's underlying mechanism, an NSAID for a nerve-damage pain source, for instance, can fail to meaningfully relieve the pain while still exposing a patient to that drug class's specific risk profile.

Common misconceptions about how painkillers work

A frequent assumption is that all painkillers work through essentially the same basic process, differing mainly in how "strong" they are. Mechanistically, this is inaccurate: NSAIDs, acetaminophen, and opioids intervene at different points in the four-stage pain pathway, which is why a drug that works well for one pain type, inflammatory joint pain, for instance, can do very little for a mechanistically different pain type, like nerve damage, regardless of how much of it is used.

A second misconception is that natural, exercise-induced pain relief works through a fundamentally different system than pharmaceutical opioids. It does not. Endorphins, the body's own endogenous opioid peptides, bind to the same mu-opioid receptors that morphine and oxycodone activate directly, meaning "runner's high" analgesia and pharmaceutical opioid analgesia share the same underlying receptor mechanism, just triggered through different means, endogenous release versus exogenous drug binding.

A third misconception, particularly relevant given the seriousness of the opioid crisis, is that tolerance and addiction are the same phenomenon. They are related but mechanistically distinct: tolerance is a receptor-level adaptation (desensitization) that can occur with any sustained opioid exposure, including legitimate long-term medical use, while addiction additionally involves the reward circuitry and the complex psychological and behavioral patterns of compulsive use despite harm. Conflating the two oversimplifies a genuinely complicated area of neuroscience and clinical medicine that researchers and physicians are still actively working to understand and manage responsibly.

The takeaway

Painkillers reduce pain through mechanistically distinct interventions at different stages of the same underlying pathway. NSAIDs block COX enzymes to reduce prostaglandin production at an injury site, lowering the pain signal at its source. Opioids bind mu-opioid receptors in the spinal cord and brain to reduce signal transmission and blunt the emotional experience of pain, a mechanism that overlaps directly with the brain's reward circuitry and is why opioids carry serious, well-documented dependence and overdose risks that NSAIDs do not share. Acetaminophen sits in a genuinely unusual scientific position: effective and widely used, but with a central mechanism still not fully mapped by researchers. Understanding these differences is not just academic. It explains why no single "strongest" painkiller exists, why chronic nerve pain often needs an entirely different drug category, and why the opioid crisis is not a failure of willpower but a consequence of receptor biology that pain medicine and public health researchers continue to study closely.

---

Read next:

• How the liver detoxifies blood
• Why fevers help fight infections
• Why muscles shake during hard exercise

FAQ

Q: How do NSAIDs like ibuprofen reduce pain?

NSAIDs inhibit cyclooxygenase (COX-1 and COX-2) enzymes, reducing production of prostaglandins, lipid compounds that sensitize nerve endings and drive inflammation at an injury site. This lowers how strong a pain signal becomes at its source, rather than changing how the brain processes a signal after it arrives.

Q: How are opioids different from NSAIDs in relieving pain?

Opioids bind to mu-opioid receptors in the spinal cord and brain, reducing transmission of pain signals to the brain and blunting the perceived unpleasantness of pain, rather than reducing inflammation at the injury site the way NSAIDs do. This central mechanism is also why opioids carry dependence risks that NSAIDs do not.

Q: Why doesn't acetaminophen reduce inflammation like NSAIDs do?

Acetaminophen's precise mechanism is not fully understood, but current evidence points to a central-nervous-system pathway distinct from peripheral COX inhibition, which would explain why it relieves pain and fever effectively without producing the strong anti-inflammatory effect typical of NSAIDs.

Q: Why do opioid painkillers carry a risk of dependence?

Mu-opioid receptors are expressed both in pain pathways and in the brain's reward circuitry, so activating them can produce euphoria alongside analgesia. Repeated activation also triggers receptor-level neuroadaptation, which drives tolerance and physical dependence, mechanisms documented in pharmacology research and central to the ongoing US opioid overdose crisis tracked by the CDC.

Q: Why do NSAIDs and opioids often fail to relieve neuropathic pain?

Neuropathic pain originates from damaged or abnormally firing nerve cells rather than active inflammation or a specific injury site, so drugs targeting prostaglandin synthesis or opioid receptors often do not address the underlying signal source, which is why nerve pain is frequently managed with different drug classes, such as certain anticonvulsants or antidepressants that stabilize nerve cell electrical activity directly.

Q: Is tolerance to opioids the same thing as addiction?

No. Tolerance is a receptor-level physiological adaptation, desensitization of mu-opioid receptors, that can occur with any sustained opioid exposure. Addiction additionally involves the brain's reward circuitry and behavioral patterns of compulsive use despite harm. The two are related and can occur together, but they are mechanistically distinct phenomena in neuroscience research.